- Home
- CUE vs ICCC Comparison
CUE vs ICCC Comparison
Compare CUE & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- ICCC
- Stock Information
- Founded
- CUE 2014
- ICCC 1982
- Country
- CUE United States
- ICCC United States
- Employees
- CUE N/A
- ICCC N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- CUE Health Care
- ICCC Health Care
- Exchange
- CUE Nasdaq
- ICCC Nasdaq
- Market Cap
- CUE 59.5M
- ICCC 60.1M
- IPO Year
- CUE 2018
- ICCC 1987
- Fundamental
- Price
- CUE $0.83
- ICCC $6.09
- Analyst Decision
- CUE Strong Buy
- ICCC
- Analyst Count
- CUE 2
- ICCC 0
- Target Price
- CUE $3.00
- ICCC N/A
- AVG Volume (30 Days)
- CUE 118.2K
- ICCC 10.7K
- Earning Date
- CUE 08-12-2025
- ICCC 08-14-2025
- Dividend Yield
- CUE N/A
- ICCC N/A
- EPS Growth
- CUE N/A
- ICCC N/A
- EPS
- CUE N/A
- ICCC 0.20
- Revenue
- CUE $8,286,000.00
- ICCC $28,274,756.00
- Revenue This Year
- CUE N/A
- ICCC N/A
- Revenue Next Year
- CUE $23.84
- ICCC N/A
- P/E Ratio
- CUE N/A
- ICCC $29.80
- Revenue Growth
- CUE N/A
- ICCC 21.75
- 52 Week Low
- CUE $0.45
- ICCC $3.34
- 52 Week High
- CUE $1.99
- ICCC $7.60
- Technical
- Relative Strength Index (RSI)
- CUE 53.58
- ICCC 44.30
- Support Level
- CUE $0.77
- ICCC $5.97
- Resistance Level
- CUE $0.84
- ICCC $6.90
- Average True Range (ATR)
- CUE 0.06
- ICCC 0.30
- MACD
- CUE -0.00
- ICCC -0.05
- Stochastic Oscillator
- CUE 71.90
- ICCC 17.23
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.